

![]() |
|||||||||||||
|
| All | Since 2021 | |
| Citation | 7304 | 4079 |
| h-index | 28 | 23 |
| i10-index | 181 | 77 |
Submit Article
Search
News & Updation
DRUG PROFILE OF SOFOSBUVIR - A NUCLEOTIDE ANALOG INHIBITOR OF THE HEPATITIS C VIRUS POLYMERASE
V.R.Ghayathri *, C.Vinodhini, S.Gayatri, K.Chitra
ABSTRACT Sofosbuvir is the drug of choice for hepatitis C virus (HCV) infection, with a high cure rate. Sofosbuvir is a component of the first all-oral, interferon-free regimen approved by FDA for treatment of chronic hepatitis C. It inhibits the RNA polymerase that the hepatitis C virus uses to replicate its RNA. This review describes the drug profile of sofosbuvir that may recommend major treatment advantages over live benefits. Keywords: Sofosbuvir, Hepatitis C , GS 331007 , FDA [Download Article] [Download Certifiate] |
